GENFIT invests up to $105M for Versantis to Up Liver Game

Genfit is spreading its bets in a rare liver disease with the buyout of Versantis, a clinical-stage biotech whose most advanced drug candidate brings a novel approach to treating a liver disease complication that has no FDA-approved therapies. And yes, Genfit already has a drug candidate on track for the treatment of acute-on-chronic liver failure (ACLF). But by acquiring Versantis, it adds another drug that works in a different way and is further along in development for the same disorder.